Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Dietary nitrate in the form of beet juice reduces restenosis after percutaneous intervention in a randomized trial.
Read Full NewsFrontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Fear of Movement, Central Sensitization May Worsen Outcomes in Gout
FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026
FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease
Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life
1.
AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI
2.
Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer
3.
How to keep your prostate healthy and lower your risk of developing serious problems
4.
Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.
5.
novel approach to test the toxicity of cancer drugs.
1.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
2.
Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology
3.
Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment
4.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
5.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge